Anti-Mouse GM-CSF Antibody (MP1-22E9)
Based on 1 publication(s) in Google Scholar
Anti-Mouse GM-CSF Antibody (MP1-22E9) is a rat-derived anti-mouse GM-CSF IgG2a antibody inhibitor. Anti-Mouse GM-CSF Antibody (MP1-22E9) can neutralize GM-CSF. Anti-Mouse GM-CSF Antibody (MP1-22E9) can be used for the researches of cancer, infection inflammation and immunology, such as cholangiocarcinoma and arthritis.
For research use only. We do not sell to patients.
- Purity: 95.49%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Anti-Mouse GM-CSF Antibody (MP1-22E9)
More
Biological Activity
Rat IgG2a kappa
Mouse
GM-CSF
Anti-Mouse GM-CSF Antibody (MP1-22E9) (72 h) significantly reduces macrophage viability in bone marrow -derived macrophages[1].
Anti-Mouse GM-CSF Antibody (MP1-22E9) (10 μg/mL, 30 mins) promotes differentiation and migration in myeloid-derived suppressor cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Anti-Mouse GM-CSF Antibody (MP1-22E9) (800 μg, i.p., every monday and thursday for 2 weeks) decreases angiogenesis in L2/IKKβca mice[2].
Anti-Mouse GM-CSF Antibody (MP1-22E9) (250 μg, i.p., at the day before curdlan injection and twice weekly for 7 weeks or 9 days after disease triggering and twice weekly until day 28) inhibits bone marrow myelopoiesis and organ inflammation in spondyloarthritis mice models[3].
Anti-Mouse GM-CSF Antibody (MP1-22E9) (200 μg, i.p., every 3 days) inhibits antitumor immunity by neutralizing GM-CSF in B16F10-OVA tumor-bearing mice models[4].
Anti-Mouse GM-CSF Antibody (MP1-22E9) (100 μg, i.p., twice a week) shows anti-tumor effect in HM-1 tumor mice models[5].
Anti-Mouse GM-CSF Antibody (MP1-22E9) (250 μg, i.p., every other day beginning one day prior to infection for 3 times) shows anti-infection effect in clostridium difficile infected mice models[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Autochthonous intrahepatic cholangiocarcinoma mice models[1]
-
Dosage:30 mg/kg
-
Administration:Intraperitoneally injection, every 2days for 4 weeks
-
Result:Suppressed tumor growth and increased latency to the development of multifocal liver tumours.
Significant reduced TAM infiltration and expression of ARG1 and PD-L1.
Significantly reduced circulating monocytes in the blood and elevated numbers of BM granulocytes.
Significantly reduced CFU in BM mononuclear cells and splenocytes.
-
Animal Model:L2/IKKβca mice[2]
-
Dosage:800 μg
-
Administration:Intraperitoneally injection, every monday and thursday for 2 weeks
-
Result:Reduced the number of CD31+ blood vessels and VWF positive endothelial cells.
-
Animal Model:Spondyloarthritis mice models[3]
-
Dosage:250 μg
-
Administration:Intraperitoneally injection, at the day before curdlan injection and twice weekly for 7 weeks or 9 days after disease triggering and twice weekly until day 28
-
Result:Decreased in LT-HSCs, MPPs and GMPs in the BM and increased CLPs cells.
Reducecd neutrophils and increased erythroid cells and B cells.
Decreased intestinal and articular neutrophil invasion.
Showed significant ameliorations in the histological and clinical scores of arthritis, marked decreases in enthesitis-associated ankle thickening and new bone formation, and inhibition of the bone surface:volume ratio increase.
Showed significant amelioration in enteritis and weight loss.
-
Animal Model:B16F10-OVA tumor-bearing mice models[4]
-
Dosage:200 μg
-
Administration:Intraperitoneally injection, every 3 days
-
Result:Reduced the IL9-inducing capacity of moDCs and cDCs.
Increased or unaffected s IFNγ induction from naive or total CD4+ T cells.
-
Animal Model:HM-1 tumor mice models[5]
-
Dosage:100 μg/mouse
-
Administration:Intraperitoneally injection, twice a week
-
Result:Suppressed tumor growth.
Decreased MDSCs.
Enhanced the efficacy of anti-VEGF abs.
-
Animal Model:Clostridium difficile infected mice models[6]
-
Dosage:250 μg/mouse
-
Administration:Intraperitoneally injection, every other day beginning one day prior to infection for 3 times
-
Result:Showed lower C. difficile colonization levels and more modest weight loss.
Reduced IL-22 levels.
Resulted in significantly lower expression of IL-1β and TNFα.
Significantly reduced expression of the ELR+ CXC chemokines CXCL1 (KC) and CXCL2 (MIP-2).
Reduced neutrophils t in colonic mucosal sections and decreased iNOS expression.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
in vivo GM-CSF neutralization; in vitro GM-CSF neutralization; Flow cytometry
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse GM-CSF Antibody (MP1-22E9)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
The E3 ligases Itch and WWP2 regulate autoimmune neuroinflammation by controlling TH2 to TH17 cell conversion via interleukin-4-STAT5 axis in mice. [Abstract]2026 Jan 23;17(1):952. PMID: 41577662
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Ruffolo LI, et al. GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity. Gut. 2022 Jul;71(7):1386-1398. [Content Brief]
[2]. Tétreault MP, et al. Esophageal Expression of Active IκB Kinase-β in Mice Up-Regulates Tumor Necrosis Factor and Granulocyte-Macrophage Colony-Stimulating Factor, Promoting Inflammation and Angiogenesis. Gastroenterology. 2016 Jun;150(7):1609-1619.e11. [Content Brief]
[3]. Regan-Komito D, et al. GM-CSF drives dysregulated hematopoietic stem cell activity and pathogenic extramedullary myelopoiesis in experimental spondyloarthritis. Nat Commun. 2020 Jan 9;11(1):155. [Content Brief]
[4]. Kim IK, et al. GM-CSF Promotes Antitumor Immunity by Inducing Th9 Cell Responses. Cancer Immunol Res. 2019 Mar;7(3):498-509. [Content Brief]
[5]. Horikawa N, et al. Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment. Br J Cancer. 2020 Mar;122(6):778-788. [Content Brief]
[6]. McDermott AJ, et al. Role of GM-CSF in the inflammatory cytokine network that regulates neutrophil influx into the colonic mucosa during Clostridium difficile infection in mice. Gut Microbes. 2014 Jul 1;5(4):476-84. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse GM-CSF Antibody (MP1-22E9) Related Classifications
HY-P99134 Related Classifications
Powered by Bioz